Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on January 21, 2020. The report addresses a significant regulatory milestone regarding the Company's New Drug Application (NDA) for SPN-812.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the acceptance by the U.S. Food and Drug Administration (FDA) of the NDA for SPN-812. This drug is intended for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 8, 2020.
Guidance, Outlook, and Risks
Outlook: The acceptance of the NDA indicates the application is complete and ready for substantive review by the FDA, with a decision expected by the November 2020 target date.
Risks: While the application is accepted for review, the filing does not explicitly detail specific risks or contingencies regarding the final approval outcome, though standard regulatory risks apply to all NDA reviews.
Investor Verification Checklist
- Verify the status of the SPN-812 NDA review process via FDA public databases.
- Confirm the PDUFA target action date of November 8, 2020, remains unchanged.
- Review the full text of the press release (Exhibit 99.1) for additional clinical data or context not summarized here.
- Monitor subsequent filings for any updates on the FDA's final decision prior to the target date.